Hemodynamic Effects of Pargyline in Hypertensive Patients

Onesti, Gaddo; Novack, Paul; Ramirez, Osvaldo; Brest, Albert N.; Moyer, John H.

doi:10.1161/01.cir.30.6.830

Cited by 25 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral treatment with debrisoquine has been reported to cause little change in renal plasma-flow and glomerular filtration rate (Abrams et al, 1964), although Onesti et al (1964) state that cardiac output, renal blood-flow, and glomerular filtration rates were decreased. Though we have not made any measurements of this kind, none of our patients showed any evidence of renal or cardiac deterioration which could be attributed to the drug.…”

Section: Discussionmentioning

confidence: 99%

Clinical observations on the effects of debrisoquine sulphate in patients with high blood-pressure.

D¹,

Cranston²,

Juel-Jensen³

et al. 1966

BMJ

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinical observations on the effects of debrisoquine sulphate in patients with high blood-pressure.

D¹,

Cranston²,

Juel-Jensen³

et al. 1966

BMJ

View full text Add to dashboard Cite

“…Pargyline and a-methyldopa also produce a further blood pressure reduction in an upright position, but the effect does not appear to be related to venous pooling. With both drugs the cardiac output is maintained at normal levels in the erect position, while the increase in peripheral resistance is abolished (91,(93)(94)(95)(98)(99)(100).…”

Section: Herrlodynamics Of Hypertensionmentioning

confidence: 99%

“…Changes in regional flow are minimal with agents which have little or no effect on cardiac output. With respect to the renal circulation, there is little change in flow with «-methyldopa (93,97) and protoveratrine (66), while pargyline (99,100) and chlorothiazide (114) produce a slight decrease in flow.…”

Section: Herrlodynamics Of Hypertensionmentioning

confidence: 99%

The Hemodynamics of Hypertension and Anti Hypertensive Therapy

Bender¹

1966

Angiology

View full text Add to dashboard Cite

It has been amply demonstrated that lowering systemic arterial pressure betters the prognosis of patients with hypertension. When the cause of the hypertension is known, the treatment of choice is the removal of the lesion. If the pathogenesis of the blood pressure elevation is unknown, however, treatment must necessarily be empirical and irrational. Despite this approach there is general agreement that controlling blood pressure with antihypertensive drugs results in a longer life expectancy for patients with essential hypertension and a reduction in the incidence of associated disabling cardiac, cerebrovascular, and renal complications (1, 2). HerrLOdynamics of hypertensionWhile there are some exceptions, especially in its early stages (3, 4), essential hypertension is associated with an increase in peripheral vascular resistance with a normal cardiac output (5-7). The cause of the elevation does not appear to be the result of increased sympathetic tone, but rather a narrowing of the resistance vessels brought about by progressive arteriosclerosis and, occasionally, degenerative changes in elastic tissue (5).Initially, it was suggested that each of the major vascular beds, with the exception of the kidney, contributed equally to the elevation in peripheral resistance. In the kidney resistance is slightly more intense, with the result that renal plasma flow is moderately reduced (8-10). On the other hand cerebral blood flow (11, 12), coronary blood flow (13), and hepatic blood flow (14,15) are within normal limits.The results of other studies (7, 16) indicate that the vasculature of skeletal muscle does not share in the increased resistance. Furthermore, the results suggest a parallel between the hemodynamic pattern of hypertension and that exhibited by normal subjects during mild exercise. In view of the unchanged cardiac output (7) and the increase in skeletal muscle flow, the results imply a reduction in flow to other major vascular beds.Objectives of antihyperten,sive therapy The primary objective of antihypertensive therapy is, of course, to reduce arterial blood pressure. It is equally apparent that it is desirable to decrease blood pressure by a mechanism which causes little or no compromise of cardiovascular function. From the examination of the relationship Blood pressure = peripheral vascular resistance X cardiac output at The University of Iowa Libraries on June 20, 2015 ang.sagepub.com Downloaded from

show abstract

“…I It has been established that methyldopa is capable of reducing the blood-pressure when given orally (Brest et al, 1961 ;Irvine et al, 1962;Onesti et al, 1962) or intravenously (Wilson et al, 1961;Gillespie et al, 1962). Sannerstedt et al (1962) found after oral methyldopa that the rises of blood-pressure induced by exercise were smaller.…”

Section: Belief In Individual Worthmentioning

confidence: 99%

Hypotensive Action of Methyldopa

Smirk¹

1963

BMJ

View full text Add to dashboard Cite

Hemodynamic Effects of Pargyline in Hypertensive Patients

Cited by 25 publications

References 15 publications

Clinical observations on the effects of debrisoquine sulphate in patients with high blood-pressure.

Clinical observations on the effects of debrisoquine sulphate in patients with high blood-pressure.

The Hemodynamics of Hypertension and Anti Hypertensive Therapy

Hypotensive Action of Methyldopa

Contact Info

Product

Resources

About